CYP7B1

Across TCGA pan-cancer cohorts, CYP7B1 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CYP7B1 data layer compared with 19 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher CYP7B1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CYP7B1 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

HNSC, UCEC, and ESCA are the cancer types where CYP7B1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	II,III,IV	0.156	0.743	.001	42	view →
UCEC	DFS	Median	II,III,IV	0.937	0.300	.005	32	view →
ESCA	OS	Median	II,III,IV	0.103	0.868	<.001	24	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CYP7B1–HNSC (OS)

Open the HNSC breakdown →